• Philips reiterated its 2026 comparable sales growth forecast of 3%-4.5%, following third-quarter growth of 3%.
• Adjusted EBITA margin guidance remains 13.5%-14%, including a U.S. tariff refund benefit of about 1 percentage point.
• Free cash flow is forecast at EUR 1.5-1.7 billion, including a net U.S. tariff refund benefit of about EUR 200 million.
• Diagnosis & Treatment growth should accelerate in the fourth quarter as delayed ultrasound shipments move through and orders convert to sales.
• The outlook assumes payment of the U.S. Justice Department settlement in first-quarter 2027; a EUR 288 million provision was recorded in third-quarter 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Koninklijke Philips NV published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.